Aethlon Medical reports Q2 net loss down to $3.0M; CEO Fisher replaced by Frakes

AETHLON MEDICAL INC

2024-Q2 EPS reported -$2.57

Net loss for fiscal Q2 2023: $3.0M vs $3.8M in prior year; operating expenses decreased 13.4% to $3.2M.
Cash balance $10.2M as of Sept 30, 2023.
CEO Charles Fisher replaced by James Frakes (Interim CEO, retains CFO role); Guy Cipriani becomes COO.
Received DCGI clearance in India for Phase 1 Hemopurifier trial in solid tumors on anti-PD-1 therapy.
Hemopurifier supply disruption continues; working with FDA for second GNA supplier; new San Diego facility.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

AETHLON MEDICAL INC reported financial results for fiscal second quarter ended September 30, 2023.

Period: fiscal second quarter ended September 30, 2023
Result: reported results

Exact text from the filing

On November 14, 2023, Aethlon Medical, Inc. issued a press release announcing its financial results for the quarter ended September 30, 2023.

View on SEC.gov

8 earnings releases filed in the last 30 days. Browse all earnings releases →

AETHLON MEDICAL INC filing history →

Source: SEC EDGAR

accession 0001683168-23-008131

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.